Tg Therapeutics Stock Performance
| TGTX Stock | USD 36.01 1.36 3.64% |
The entity owns a Beta (Systematic Risk) of 0.82, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, TG Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding TG Therapeutics is expected to be smaller as well. At this point, TG Therapeutics has a negative expected return of -0.15%. Please make sure to validate TG Therapeutics' value at risk, and the relationship between the standard deviation and kurtosis , to decide if TG Therapeutics performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days TG Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest conflicting performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return (3.64) | Five Day Return (11.33) | Year To Date Return 15.94 | Ten Year Return 141.84 | All Time Return (84.00) |
Last Split Factor 100:5625 | Last Split Date 2012-04-30 |
1 | TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals | 04/07/2025 |
2 | TG Therapeutics raises 2025 guidance to 560M, driven by BRIUMVI adoption | 05/05/2025 |
3 | Biotech Stocks To Keep An Eye On May 5th | 05/06/2025 |
4 | Fluor Corporation Among Billionaire Louis Bacons Stock Picks with Huge Upside Potential | 05/07/2025 |
5 | TG Therapeutics, Inc. Shares Purchased by Northern Trust Corp | 05/09/2025 |
6 | Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | 05/15/2025 |
7 | TG Therapeutics Inc Announces Presentation Schedule for B | 05/27/2025 |
8 | TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 ... | 05/30/2025 |
9 | Acquisition by Power Sean A of 25000 shares of TG Therapeutics subject to Rule 16b-3 | 06/03/2025 |
10 | TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference | 06/06/2025 |
11 | TG Therapeutics Approves Key Proposals at Annual Meeting - TipRanks | 06/13/2025 |
| Begin Period Cash Flow | 94.2 M |
TG Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,106 in TG Therapeutics on March 16, 2025 and sell it today you would lose (505.00) from holding TG Therapeutics or give up 12.3% of portfolio value over 90 days. TG Therapeutics is currently does not generate positive expected returns and assumes 3.3766% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than TGTX, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TG Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TG Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as TG Therapeutics, and traders can use it to determine the average amount a TG Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0446
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TGTX |
Estimated Market Risk
| 3.38 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average TG Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TG Therapeutics by adding TG Therapeutics to a well-diversified portfolio.
TG Therapeutics Fundamentals Growth
TGTX Stock prices reflect investors' perceptions of the future prospects and financial health of TG Therapeutics, and TG Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TGTX Stock performance.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0726 | ||||
| Profit Margin | 0.10 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 5.59 B | ||||
| Shares Outstanding | 158.76 M | ||||
| Price To Earning | (4.14) X | ||||
| Price To Book | 24.09 X | ||||
| Price To Sales | 14.80 X | ||||
| Revenue | 329 M | ||||
| Gross Profit | 337.8 M | ||||
| EBITDA | 49.9 M | ||||
| Net Income | 23.38 M | ||||
| Cash And Equivalents | 195.71 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 254.38 M | ||||
| Debt To Equity | 0.62 % | ||||
| Current Ratio | 4.68 X | ||||
| Book Value Per Share | 1.63 X | ||||
| Cash Flow From Operations | (40.52 M) | ||||
| Earnings Per Share | 0.25 X | ||||
| Market Capitalization | 5.72 B | ||||
| Total Asset | 577.69 M | ||||
| Retained Earnings | (1.53 B) | ||||
| Working Capital | 475.68 M | ||||
| Current Asset | 71.33 M | ||||
| Current Liabilities | 16.88 M | ||||
About TG Therapeutics Performance
Evaluating TG Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if TG Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TG Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1 K | 995 | |
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.09 | 0.07 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.11 | 0.11 |
Things to note about TG Therapeutics performance evaluation
Checking the ongoing alerts about TG Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TG Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TG Therapeutics generated a negative expected return over the last 90 days | |
| TG Therapeutics has high historical volatility and very poor performance | |
| TG Therapeutics currently holds about 195.71 M in cash with (40.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| TG Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: TG Therapeutics Approves Key Proposals at Annual Meeting - TipRanks |
- Analyzing TG Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TG Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining TG Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TG Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TG Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TG Therapeutics' stock. These opinions can provide insight into TG Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.